Skip to main content
. Author manuscript; available in PMC: 2013 Aug 1.
Published in final edited form as: Pharmacol Ther. 2012 May 22;135(2):176–181. doi: 10.1016/j.pharmthera.2012.05.005

Table 2.

Lung Function Characteristics of SARP Cohort (Moore et al., 2007)

Baseline Lung Function Mild N Moderate N Severe N P value*
 FEV1% predicted 94 ± 11 164 66 ± 11 70 62 ± 22 204 <0.0001
 FVC % predicted 100 ± 12 81 ± 13 77 ± 20 <0.0001
 FEV1/FVC (%) 80 ± 7 67 ± 10 65 ± 13 <0.0001
Best lung function 157 60 185
 FEV1% predicted 102 ± 11 79 ± 12 77 ± 21 <0.0001
 FVC % predicted 103 ± 13 91 ± 14 91 ± 18 <0.0001
 Maximal % change in FEV1 9 ± 7 20 ± 16 20 ± 24 <0.0001
Methacholine PC 20 (log mg/mL) 0.24 ± 0.62 133 −0.11 ± 0.54 46 −0.06 ± 0.7 87 0.002

Three way comparison, significant because of differences between mild vs. moderate and severe The magnitude of bronchodilator reversibility (9% vs. 20% and 20%, for mild vs. moderate and severe, respectively) correlated with the level of FEV1% predicted, P <0.0001 (94% vs. 66% and 62% for mild vs. moderate and severe, respectively) but not with disease severity classification (mild, moderate or severe).